Dapsone gel (marketed as ACZONE®) was FDA approved on February 25, 2016, specifically for the treatment of acne vulgaris in patients 12 years and older, and the clinical data shows it works particularly well for adult women with inflammatory acne. In clinical trials, 53.5% of adult women achieved clinical success—defined as no or minimal acne—at 12 weeks using the 5% formulation, compared to 45.3% in adolescent females, suggesting that the medication’s efficacy profile tilts in favor of the adult demographic. The drug reduced inflammatory lesions by an average of 15.8 lesions (54.6% reduction) versus 13.9 lesions with a placebo control, making it one of the more effective topical options for women dealing with stubborn acne well into adulthood. This article covers what dapsone gel is, why it tends to work better for adult women than younger patients, what clinical results you can realistically expect, how to use it correctly, its safety profile, what it actually costs with and without insurance, and the emerging research suggesting it may have applications beyond acne treatment.
Table of Contents
- What Is Dapsone Gel and How Did It Become FDA Approved?
- Why Does Dapsone Gel Work Better in Adult Women Than Other Demographics?
- What Clinical Results Can You Realistically Expect?
- Dosing, Application, and Which Formulation Is Right for You?
- Safety, Side Effects, and What to Expect in the First Few Weeks
- Cost, Insurance Coverage, and Making Dapsone Affordable
- Beyond Acne—Emerging Research and Future Applications
- Conclusion
What Is Dapsone Gel and How Did It Become FDA Approved?
Dapsone is an older antibiotic that’s been used systemically for decades to treat conditions like leprosy and certain skin infections. The topical gel formulation was a relatively recent development—ACZONE® 7.5% received FDA approval in February 2016, with the product becoming available nationwide by May 2016. Allergan, the pharmaceutical company behind the product, conducted one of the largest acne studies to support the approval: a pivotal trial involving 4,340 acne patients, with 2,162 randomized to ACZONE® Gel 7.5% and 2,178 to placebo control.
The FDA found no major safety issues or previously unrecognized safety signals, which cleared the way for approval. The drug became available in two different formulations: a 5% gel requiring twice-daily application, and a 7.5% gel requiring just once-daily application. This dosing flexibility was important because it allowed dermatologists to tailor treatment to patient preferences and skin tolerance. The once-daily 7.5% option proved particularly popular because adherence tends to improve when treatments require fewer daily applications—a critical consideration since acne treatment success depends heavily on consistent use.
Why Does Dapsone Gel Work Better in Adult Women Than Other Demographics?
The clinical data reveals a striking disparity: female patients with acne showed a 46.6% mean reduction in total lesion counts versus just 34.4% in male patients. Even more impressive, 48.6% of women achieved clinical success compared to only 34.4% of men in the same trials. This difference isn’t fully understood, but likely relates to hormonal factors—adult female acne often has an inflammatory component driven by sensitivity to androgens, and dapsone’s anti-inflammatory properties may be particularly well-suited to address this mechanism.
Additionally, women tend to be more compliant with twice-daily regimens, which could contribute to better outcomes in the 5% formulation. For women with skin of color specifically, the data showed a 39.0% improvement in Global Acne Assessment Score from baseline to 12 weeks, indicating the drug performs reliably across different skin types without the hyperpigmentation or hypopigmentation issues that can complicate acne treatment in darker skin tones. This makes dapsone gel a relatively safer choice for an underserved population, though individual results still vary. However, if you have very sensitive skin or a history of severe dermatitis, dapsone isn’t necessarily a magic solution—the mild local side effects like dryness and peeling can still trigger flare-ups in reactive skin.
What Clinical Results Can You Realistically Expect?
The headline numbers are encouraging: 53.5% of adult women achieved “clinical success” (minimal to no acne) within 12 weeks using the 5% formulation. Translated to inflammatory lesions specifically, the average reduction was 15.8 lesions over 12 weeks—meaning someone starting with, say, 30 inflammatory lesions could expect to drop to around 12 by week 12. This is a significant improvement, though not complete clearance for everyone.
The data for the 7.5% gel showed similar efficacy with the convenience of once-daily dosing, making it the more popular option in real practice. When dapsone is used as a monotherapy (the drug alone, without other acne treatments), treatment success rates range from 40.1% to 69.4% for the 5% formulation and 29.8% to 47.0% for the 7.5% formulation over 12 to 16 weeks, depending on the specific patient population and study. This wide range highlights a key limitation: dapsone works very well for some women but not as well for others. Dermatologists often combine dapsone gel with other treatments—like oral contraceptives for hormonal acne or benzoyl peroxide for additional antimicrobial coverage—to improve overall results, especially in cases of moderate to severe acne.
Dosing, Application, and Which Formulation Is Right for You?
The two formulations reflect a practical tradeoff between strength and convenience. The 5% gel requires twice-daily application (morning and evening), while the 7.5% gel needs only once-daily application, typically in the evening. Many dermatologists recommend starting with the 5% formulation if you have sensitive skin, because lower concentrations tend to produce fewer side effects while still delivering meaningful results. However, if you have more severe inflammatory acne or if you know you’ll struggle with twice-daily adherence, the 7.5% once-daily option may be the better choice despite being slightly stronger.
Dapsone gel should be applied to clean, dry skin—washing with a gentle cleanser and waiting a few minutes for your skin to fully dry before application ensures better penetration and reduces irritation. Many patients apply it to the entire face or to problem areas, depending on their acne distribution. The key to seeing results is consistency: you’re looking at a minimum of 4 weeks before noticeable improvement, with fuller results typically visible by week 12. If you stop applying it regularly or miss doses frequently, the acne will often rebound, which is why the once-daily formulation has become increasingly popular in clinical practice.
Safety, Side Effects, and What to Expect in the First Few Weeks
The safety profile of topical dapsone is quite favorable because the drug is absorbed minimally through the skin, meaning serious systemic side effects are rare. The adverse effects that do occur are almost always mild and localized to the skin: dryness, erythema (redness), peeling, flaking, tightness, and stinging sensations. These typically appear in the first 1-2 weeks and often improve as your skin adjusts. Importantly, serious safety signals didn’t emerge even in the largest clinical trial (4,340 patients), which suggests the risk profile is genuinely low.
However, if you have severe rosacea, active dermatitis, or compromised skin barrier function, dapsone gel can exacerbate these conditions. The drug’s anti-inflammatory action doesn’t mean it’s universally safe for all skin conditions—in fact, the peeling and dryness it causes can worsen certain types of sensitive skin. If you’re also using other potentially irritating products like retinoids or high-concentration vitamin C serums, combining them with dapsone immediately may be too much for your skin. Many dermatologists recommend introducing dapsone first, letting your skin adapt, and then slowly adding other actives rather than layering everything at once.
Cost, Insurance Coverage, and Making Dapsone Affordable
The sticker price for ACZONE® gel is substantial: approximately $1,078.15 for a 60-gram pump bottle at full retail without insurance, making it one of the pricier acne treatments out of pocket. However, several affordability options exist. With discount programs like GoodRx or similar pharmacy discount cards, the cost drops dramatically to $45.37 to $118.99 depending on your pharmacy choice. Allergan also offers a manufacturer coupon that caps your out-of-pocket cost at no more than $35 per prescription for up to three fills, which is a meaningful subsidy if you qualify.
A critical point many patients overlook: generic dapsone is available as a much cheaper alternative, starting at around $50.16 for a 60-gram tube of the 5% formulation. This generic option delivers the same active ingredient and is equally effective, making it an excellent choice if you’re uninsured or if your insurance doesn’t cover the brand name. The main tradeoff is that you’ll be paying out of pocket and may need to find a compounding pharmacy that can prepare it, but the savings are substantial enough that it’s worth exploring if cost is a concern. Most insurance plans do eventually cover ACZONE® after prior authorization, particularly if you’ve tried over-the-counter options first, so checking with your plan is also worthwhile.
Beyond Acne—Emerging Research and Future Applications
Recent clinical research has expanded the scope of dapsone gel beyond acne treatment. Emerging studies from 2025 and 2026 show promising results in treating pustular psoriasis, granuloma faciale, and other inflammatory and granulomatous skin disorders. The anti-inflammatory mechanism that works so well for acne appears to be beneficial in other conditions characterized by pustules and inflammation, though these applications are still considered off-label and not yet officially approved by the FDA.
This expanding evidence base suggests dermatologists may increasingly reach for dapsone gel in a wider range of inflammatory skin conditions over the coming years. The drug’s favorable safety profile and topical delivery make it an attractive option for conditions that might otherwise require oral medications with systemic side effects. However, it’s important to note that these expanded uses are still in clinical investigation phases, and if your dermatologist is considering dapsone for something other than acne, it’s worth asking about the strength of evidence for that particular condition.
Conclusion
Dapsone gel (ACZONE®) has solid clinical evidence supporting its effectiveness for inflammatory acne in adult women, with FDA approval dating back to 2016 and clinical success rates around 53.5% in adult female populations. The drug offers two formulations (5% twice daily and 7.5% once daily) with favorable safety profiles, mild and usually temporary side effects, and multiple affordability options ranging from generic alternatives at $50 to brand-name versions with manufacturer coupons capped at $35.
The clinical data is particularly compelling for women with hormonal acne and women with skin of color, populations often underserved by existing acne treatments. If you’re considering dapsone gel, the most practical next step is a consultation with a dermatologist who can assess whether your acne profile matches the drug’s strengths—particularly if you have inflammatory lesions, moderate acne that hasn’t responded to conventional treatments, or if you prefer a topical option over oral medications. Bring up both formulations and the generic option to discuss which fits your life and budget, and plan to give the treatment at least 12 weeks at consistent daily application before assessing whether it’s working for you.
